Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation reports company developments tied to immune-driven diagnostics and immune medicine. The commercial-stage biotechnology company applies a proprietary platform to translate adaptive immune system genetics into clinical products, with operating activity organized around Minimal Residual Disease (MRD) and Immune Medicine.
Recurring updates for ADPT include clonoSEQ MRD testing adoption, MRD revenue trends, pharma regulatory milestone revenue, operating expense guidance, and quarterly financial results. Company news also covers immune receptor and TCR-antigen data partnerships, autoimmune and cancer-related research applications, investor conference participation, and management commentary on the company’s diagnostic and drug-development collaborations.
Adaptive Biotechnologies (Nasdaq: ADPT) announced that its next-generation sequencing clonoSEQ® MRD test is featured in 89 abstracts, including 36 oral presentations, at the 67th ASH Annual Meeting scheduled for Dec. 6–9, 2025 in Orlando.
Abstracts cover multiple myeloma, ALL, CLL, MCL, DLBCL and other blood cancers, with more than 17 presentations showing clonoSEQ informing real-world treatment decisions and expanded use in clinical trials across modalities such as CAR T and bispecific antibodies.
Adaptive Biotechnologies (Nasdaq: ADPT) will participate in two investor conferences in late 2025: a presentation at the Jefferies Global Healthcare Conference in London on November 19, 2025 at 8:00 a.m. GMT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 8:30 a.m. ET.
Interested parties may access live and archived webcasts on the company’s Investors section at www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) reported third quarter 2025 results on November 5, 2025, showing strong MRD momentum and updated guidance.
Key points: Q3 revenue $94.0M (includes $33.7M one-time Genentech amortization); excluding Genentech $60.2M (+40% YoY). MRD revenue $56.8M (+52% YoY) with clonoSEQ volume 27,111 (+38% YoY). MRD achieved cash flow positivity and an MRD Adjusted EBITDA of $7.0M. Company Adjusted EBITDA was $28.0M. Cash and marketable securities were $216.8M. Company raised full-year MRD guidance to $202–$207M and narrowed operating spend and cash burn guidance.
Adaptive Biotechnologies (Nasdaq: ADPT) will report third quarter 2025 financial results after market close on Wednesday, November 5, 2025. Management will host a webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors web page at www.adaptivebiotech.com, and the webcast will be archived and available for replay within 24 hours.
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York.
Management will engage in a fireside chat on September 10th at 1:05 PM ET. Investors can access both live and archived webcasts of the presentation through the company's website investor section at adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) reported strong Q2 2025 financial results, with total revenue reaching $58.9 million, a 36% year-over-year increase. The company's MRD business, contributing 85% of revenue, achieved profitability with $1.9 million in Adjusted EBITDA and 42% growth to $49.9 million.
Key highlights include 37% growth in clonoSEQ test volume to 25,321 tests, integration with Flatiron's OncoEMR platform, and implementation of NovaSeq X Plus for clinical sequencing. The company raised its 2025 MRD revenue guidance to $190-200 million and reduced cash burn guidance to $45-55 million.
Despite progress, the company reported a net loss of $25.6 million, though improved from $46.2 million in Q2 2024. Cash position remains strong at $222.0 million as of June 30, 2025.
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotech company focused on adaptive immune system applications, has scheduled its Q2 2025 financial results announcement for August 5, 2025 after market close.
The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can access the live webcast through the company's website investor section, with a replay available within 24 hours after the event.
Adaptive Biotechnologies (NASDAQ: ADPT) has announced a strategic integration of its clonoSEQ® test for measurable residual disease (MRD) assessment into Flatiron Health's OncoEMR® platform. The integration provides streamlined access to MRD testing for over 4,500 clinicians across 1,000 community-based cancer care locations in the United States.
The integration, effective July 1, 2025, enables healthcare providers to order and review clonoSEQ MRD testing results directly within the Electronic Medical Record system. This development aims to improve testing workflows and provide real-time insights into patient disease status, particularly for blood cancer patients. The clonoSEQ test helps detect small numbers of cancer cells that may remain during and after treatment, serving as a key predictor of patient outcomes.
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on adaptive immune system genetics, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. The company's management will engage in a fireside chat on June 11th at 5:40 a.m. PT / 8:40 a.m. ET. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website investor section at www.adaptivebiotech.com.